Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Drs Roeth and Kulasekararaj contributed equally as authors. Background: Iptacopan is the first oral complement inhibitor that acts proximally in the complement system to target factor B in the alternative pathway. Iptacopan has shown efficacy/safety in PNH pts with persistent anemia despite anti-C5...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.571-571
Hauptverfasser:	Risitano, Antonio M, Kulasekararaj, Austin, Roeth, Alexander, Scheinberg, Phillip, Ueda, Yasutaka, de Castro, Carlos, Di Bona, Eros, Griffin, Morag, Langemeijer, Saskia MC, Schrezenmeier, Hubert, Barcellini, Wilma, Mauad, Vitor AQ, Panse, Jens, Schafhausen, Philippe, Tavitian, Suzanne, Beggiato, Eloise, Gaya, Anna, Huang, Wei-Han, Kitawaki, Toshio, Kutlar, Abdullah, Maciejewski, Jaroslaw P., Notaro, Rosario, Pullarkat, Vinod, Schubert, Jörg, Terriou, Louis, Uchiyama, Michihiro, Sicre De Fontbrune, Flore, Frieri, Camilla, Alashkar, Ferras, Gandhi, Shreyans, Kumar, Rakesh, Thorburn, Christine, Maitra, Samopriyo, Solar-Yohay, Susan, Lawniczek, Tomasz, Dahlke, Marion, Peffault De Latour, Régis
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!